Versant Ventures VI GP-GP, LLC 4
4 · Akero Therapeutics, Inc. · Filed Jan 15, 2020
Insider Transaction Report
Form 4
Versant Venture Capital VI, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-01-10$20.10/sh−19,343$388,794→ 3,183,724 total(indirect: See Footnote) - Sale
Common Stock
2020-01-13$20.84/sh−83$1,730→ 3,172,048 total(indirect: See Footnote) - Sale
Common Stock
2020-01-13$20.16/sh−11,593$233,715→ 3,172,131 total(indirect: See Footnote) - Sale
Common Stock
2020-01-15$19.73/sh−7,511$148,192→ 3,152,230 total(indirect: See Footnote) - Sale
Common Stock
2020-01-14$20.00/sh−12,307$246,140→ 3,159,741 total(indirect: See Footnote)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
- [F2]These sales were executed in multiple trades at prices ranging from $19.80 to $20.28. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F3]These sales were executed in multiple trades at prices ranging from $19.76 to $20.72. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F4]These sales were executed in multiple trades at prices ranging from $19.71 to $20.33. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F5]These sales were executed in multiple trades at prices ranging from $19.67 to $19.86. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
- [F6]These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein.